Welcome to our dedicated page for Novavax SEC filings (Ticker: NVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing the hundreds of pages in Novavax’s regulatory reports can feel like reading a clinical protocol—dense tables of trial data, Matrix-M® manufacturing clauses, and milestone payments buried in footnotes. If you’ve ever wondered how to locate the precise wording on government funding or track when executives sell shares before pivotal readouts, this page solves the problem.
Stock Titan applies AI to every Novavax SEC filing, turning complex biotech jargon into plain-English insights. Open a Novavax annual report 10-K simplified summary to see R&D spend by vaccine program, or view the latest Novavax quarterly earnings report 10-Q filing with trial-cost breakdowns already highlighted. Our engine flags each Novavax 8-K material events explained notice within minutes of hitting EDGAR, and it delivers Novavax Form 4 insider transactions real-time so you can follow leadership’s moves as they happen.
Key use cases include:
- Comparing funding trends across COVID-19, RSV, and influenza programs with Novavax earnings report filing analysis
- Monitoring Novavax executive stock transactions Form 4 before data releases
- Reviewing Novavax proxy statement executive compensation to see how trial milestones influence pay
- Quickly scanning risk-factor changes using “Novavax SEC filings explained simply” AI summaries
Whether you need detailed footnotes on BARDA contracts or just a snapshot of Novavax insider trading Form 4 transactions, our platform delivers every document with real-time alerts, clear context, and searchable AI annotations—making understanding Novavax SEC documents with AI straightforward.
Novavax director Richard J. Rodgers received new equity compensation grants on June 20, 2025, consisting of:
- 28,326 stock options with an exercise price of $6.42 per share, exercisable until June 20, 2035
- 18,884 Restricted Stock Units (RSUs) convertible into common stock
Both grants are scheduled to vest 100% on the first anniversary of the grant date (June 20, 2024), contingent on continued service as a board member. The stock options represent the right to purchase Novavax common stock, while each RSU represents the right to receive one share of common stock upon vesting. This compensation package aligns with standard director equity incentive practices under the company's Amended and Restated 2015 Stock Incentive Plan.
Novavax director David M. Mott reported two significant equity compensation grants on June 20, 2025:
- Received 28,326 stock options with an exercise price of $6.42, exercisable until June 20, 2035. These options will fully vest on June 20, 2025, contingent on continued board service.
- Granted 18,884 Restricted Stock Units (RSUs) that will fully vest on June 20, 2025, subject to continued board service. Each RSU represents the right to receive one share of common stock.
The equity grants are part of Novavax's Amended and Restated 2015 Stock Incentive Plan. The one-year cliff vesting structure for both awards suggests standard annual director compensation. The filing was signed by Mark J. Casey as attorney-in-fact on June 24, 2025.
Novavax director Rachel K. King reported new equity compensation grants on June 20, 2025, consisting of:
- Stock Options: Received 28,326 options to purchase common stock at $6.42 per share, exercisable until June 20, 2035. These options will fully vest on June 20, 2025, subject to continued board service.
- Restricted Stock Units (RSUs): Granted 18,884 RSUs that convert to common stock shares. The RSUs will fully vest on June 20, 2025, contingent on continued board service.
The equity grants were made under Novavax's Amended and Restated 2015 Stock Incentive Plan. The Form 4 was filed by Mark J. Casey as attorney-in-fact on June 24, 2025. This compensation package aligns the director's interests with shareholders through both appreciation-based options and full-value RSUs.
Novavax director Richard Douglas received new equity compensation grants on June 20, 2025, consisting of:
- 28,326 stock options with an exercise price of $6.42 per share, exercisable until June 20, 2035
- 18,884 restricted stock units (RSUs) representing the right to receive an equal number of common shares
Both grants will fully vest on the first anniversary of the grant date (June 20, 2024), subject to continued service on the Board of Directors. The stock options were granted under Novavax's Amended and Restated 2015 Stock Incentive Plan. This Form 4 filing represents standard board of director equity compensation and was reported by Mark J. Casey as attorney-in-fact on June 24, 2025.
Novavax director Gregg H. Alton received new equity compensation grants on June 20, 2025, as reported in this Form 4 filing. The awards consist of:
- Stock Options: 28,326 options to purchase common stock at an exercise price of $6.42, expiring June 20, 2035
- Restricted Stock Units (RSUs): 18,884 RSUs, each convertible into one share of common stock
Both grants will fully vest on the first anniversary of the grant date (June 20, 2024), contingent on Alton's continued service on Novavax's Board of Directors. The RSUs were granted under the company's Amended and Restated 2015 Stock Incentive Plan. This compensation structure aligns the director's interests with shareholders through both appreciation potential (options) and direct equity ownership (RSUs).
Novavax director Margaret G. McGlynn received new equity compensation grants on June 20, 2025, as reported in this Form 4 filing. The awards consist of:
- Stock Options: 28,326 options to purchase common stock at an exercise price of $6.42, expiring June 20, 2035
- Restricted Stock Units (RSUs): 18,884 RSUs, each convertible into one share of common stock
Both grants will fully vest on the first anniversary of the grant date (June 20, 2024), contingent on McGlynn's continued service on the Board of Directors. The options and RSUs were awarded under Novavax's Amended and Restated 2015 Stock Incentive Plan. This appears to be standard annual director compensation, providing both immediate value through RSUs and potential upside through stock options.
Novavax held its Annual Meeting on June 20, 2025, with 95,359,194 shares represented out of 161,968,503 total outstanding shares. Three key proposals were voted upon:
1. Board Elections: Three Class III directors were elected for three-year terms:
- Rachel K. King (38.3M for, 19.1M against)
- John W. Shiver (43.7M for, 13.8M against)
- Charles W. Newton (42.8M for, 14.6M against)
2. Executive Compensation: Shareholders approved named executive officers' compensation in an advisory vote (41.3M for, 15.8M against)
3. Auditor Appointment: Ernst & Young LLP was ratified as independent auditor for FY2025 with strong approval (79.3M for, 15.1M against)
FAQ
What is the current stock price of Novavax (NVAX)?
What is the market cap of Novavax (NVAX)?
What is Novavax Inc's core technology?
Which infectious diseases does Novavax target?
How does the Matrix-M adjuvant work?
What is the significance of Novavax's clinical-stage pipeline?
How does Novavax generate value through partnerships?
What distinguishes Novavax from other vaccine developers?
Where is Novavax Inc headquartered?
